Vanguard Group Inc Synaptogenix, Inc. Transaction History

Vanguard Group Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$0.23 - $0.4 $11,760 - $20,452	51,131 Added 294.01%	68,522 $18,000
Q3 2023 Nov 14, 2023	SELL	$0.28 - $1.04 $651 - $2,421	-2,328 Reduced 11.81%	17,391 $7,000
Q1 2023 May 15, 2023	SELL	$0.8 - $1.33 $162,348 - $269,903	-202,935 Reduced 91.14%	19,719 $15,000
Q4 2022 Feb 10, 2023	BUY	$1.02 - $181.75 $162 - $28,898	159 Added 0.07%	222,654 $258,000
Q3 2022 Nov 14, 2022	BUY	$4.6 - $172.25 $26,031 - $974,762	5,659 Added 2.61%	222,495 $1.49 Million
Q1 2022 May 13, 2022	BUY	$6.31 - $10.09 $976,081 - $1.56 Million	154,688 Added 248.9%	216,836 $1.68 Million
Q4 2021 Feb 14, 2022	BUY	$8.38 - $13.72 $520,800 - $852,670	62,148 New	62,148 $529,000

30K

Ticker SNPX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 6,840,630
Market Cap $20.2M
Description
Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. The company is also evaluating therapeutic applications of bryostatin for other neurodeg...

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

Stay updated on Vanguard Group Inc with notifications on news.